Literature DB >> 21629216

Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?

Katrien De Bock1, Massimiliano Mazzone, Peter Carmeliet.   

Abstract

All human cells, including cancer cells, need oxygen and nutrients to survive. A widely used strategy to combat cancer is therefore the starvation of tumor cells by cutting off the blood supply of tumors. Clinical experience indeed shows that tumor progression can be delayed by anti-angiogenic agents. However, emerging evidence indicates that in certain experimental conditions, hypoxia as a result of pruning of the tumor microvasculature can promote tumor invasion and metastasis, although these findings are contextual and debated. Genetic studies in mice unveiled that vascular-targeting strategies that avoid aggravation of tumor hypoxia or even promote tumor oxygenation might prevent such an invasive metastatic switch. In this article, we will discuss the emerging link between hypoxia signaling and the various steps of metastasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21629216     DOI: 10.1038/nrclinonc.2011.83

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  148 in total

1.  Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor.

Authors:  D H Rowe; J Huang; M L Kayton; R Thompson; A Troxel; K M O'Toole; D Yamashiro; C J Stolar; J J Kandel
Journal:  J Pediatr Surg       Date:  2000-01       Impact factor: 2.545

2.  C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells.

Authors:  Sachie Hiratsuka; Dan G Duda; Yuhui Huang; Shom Goel; Tatsuki Sugiyama; Takashi Nagasawa; Dai Fukumura; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

3.  Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage.

Authors:  Young Jun Koh; Hak-Zoo Kim; Seong-Ik Hwang; Jeung Eun Lee; Nuri Oh; Keehoon Jung; Minah Kim; Kyung Eun Kim; Homin Kim; Nam-Kyu Lim; Choon-Ju Jeon; Gyun Min Lee; Byeong Hwa Jeon; Do-Hyun Nam; Hoon Ki Sung; Andras Nagy; Ook Joon Yoo; Gou Young Koh
Journal:  Cancer Cell       Date:  2010-08-09       Impact factor: 31.743

Review 4.  Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis.

Authors:  M P Kim; S I Park; S Kopetz; G E Gallick
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

Review 5.  Hypoxia helps glioma to fight therapy.

Authors:  Verena Amberger-Murphy
Journal:  Curr Cancer Drug Targets       Date:  2009-05       Impact factor: 3.428

Review 6.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

7.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

8.  Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4.

Authors:  H U Wang; Z F Chen; D J Anderson
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

Review 9.  FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

Authors:  Christian Fischer; Massimiliano Mazzone; Bart Jonckx; Peter Carmeliet
Journal:  Nat Rev Cancer       Date:  2008-12       Impact factor: 60.716

10.  Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.

Authors:  Ymera Pignochino; Giovanni Grignani; Giuliana Cavalloni; Manuela Motta; Marta Tapparo; Stefania Bruno; Alessia Bottos; Loretta Gammaitoni; Giorgia Migliardi; Giovanni Camussi; Marco Alberghini; Bruno Torchio; Stefano Ferrari; Federico Bussolino; Franca Fagioli; Piero Picci; Massimo Aglietta
Journal:  Mol Cancer       Date:  2009-12-10       Impact factor: 27.401

View more
  114 in total

1.  Angiogenesis inhibitors increase tumor stem cells.

Authors:  Cindy H Chau; William D Figg
Journal:  Cancer Biol Ther       Date:  2012-06-01       Impact factor: 4.742

Review 2.  Overcoming resistance to antiangiogenic therapies.

Authors:  Sabine Tejpar; Hans Prenen; Massimiliano Mazzone
Journal:  Oncologist       Date:  2012-07-06

3.  A pyrrole-based natural small molecule mitigates HSP90 expression in MDA-MB-231 cells and inhibits tumor angiogenesis in mice by inactivating HSF-1.

Authors:  K C Rashmi; H S Atreya; M Harsha Raj; Bharathi P Salimath; H S Aparna
Journal:  Cell Stress Chaperones       Date:  2017-07-17       Impact factor: 3.667

Review 4.  Can oncology recapitulate paleontology? Lessons from species extinctions.

Authors:  Viola Walther; Crispin T Hiley; Darryl Shibata; Charles Swanton; Paul E Turner; Carlo C Maley
Journal:  Nat Rev Clin Oncol       Date:  2015-02-17       Impact factor: 66.675

Review 5.  Steps in metastasis: an updated review.

Authors:  Jamal Majidpoor; Keywan Mortezaee
Journal:  Med Oncol       Date:  2021-01-04       Impact factor: 3.064

6.  VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations.

Authors:  Virginie Hervé; Nathalie Rabbe; Laurent Guilleminault; Flora Paul; Laurène Schlick; Nicolas Azzopardi; Michael Duruisseaux; Delphine Fouquenet; Jérôme Montharu; Françoise Redini; Gilles Paintaud; Etienne Lemarié; Jacques Cadranel; Marie Wislez; Nathalie Heuzé-Vourc'h
Journal:  MAbs       Date:  2014       Impact factor: 5.857

7.  Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development.

Authors:  Paulina Kucharzewska; Helena C Christianson; Johanna E Welch; Katrin J Svensson; Erik Fredlund; Markus Ringnér; Matthias Mörgelin; Erika Bourseau-Guilmain; Johan Bengzon; Mattias Belting
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

Review 8.  The gastrointestinal tumor microenvironment.

Authors:  Michael Quante; Julia Varga; Timothy C Wang; Florian R Greten
Journal:  Gastroenterology       Date:  2013-04-10       Impact factor: 22.682

9.  Identification of pY654-β-catenin as a critical co-factor in hypoxia-inducible factor-1α signaling and tumor responses to hypoxia.

Authors:  Y Xi; Y Wei; B Sennino; A Ulsamer; I Kwan; A N Brumwell; K Tan; M K Aghi; D M McDonald; D M Jablons; H A Chapman
Journal:  Oncogene       Date:  2012-12-17       Impact factor: 9.867

Review 10.  Heterogeneity of glycolysis in cancers and therapeutic opportunities.

Authors:  Marc O Warmoes; Jason W Locasale
Journal:  Biochem Pharmacol       Date:  2014-08-02       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.